Seno Medical Instruments (San Antonio, Texas) received European CE Mark approval for its Imagio opto-acoustic breast imaging system. It’s currently being investigated in the U.S. in a study to determine whether it can help avoid unnecessary biopsies by identifying whether a suspicious lesion is likely cancerous.
The system provides information about blood vasculature around a suspected mass, helping to identify a true tumor based on neovascularization that typically exist around a cancerous lesion.
From the announcement:
Unlike other functional fusion technologies, Imagio uses no x-rays (ionizing radiation) or injectable contrast agents to obtain its information, thereby reducing the patient’s exposure to any potentially harmful aspects of imaging.
In 2012, The European Journal of Cancer estimated that 464,000 new cases of breast cancer were diagnosed in Europe.1Each year millions of women around the world undergo core needle or surgical breast biopsies after a suspicious mass is found through breast imaging or self-exams. Studies show that more than 80% of these biopsies reveal benign pathology2after they are analyzed in a laboratory.